Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute said its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled, with topline results expected in mid-December 2026. The announcement provides a clinical-trial milestone and a defined data timeline, but reports no efficacy or safety results.

Analysis

Enrollment completion removes execution risk, not clinical risk. For RZLT, the key near-term driver is the mid-December topline readout: with roughly two months until the catalyst, the stock may increasingly trade as a binary event, and a favorable headline could matter more than the underlying commercial value until endpoint details are clear. The open-label design raises interpretation risk; verify the prespecified endpoint, evaluable patient count, magnitude and durability of response, safety, and whether results support the intended regulatory path. The article supplies none of these details, nor cash runway or valuation, so financing exposure and risk/reward cannot be quantified.

Over 1–3 months, a clean, clinically meaningful result could improve confidence in development and bring the next regulatory milestone into focus; weak or ambiguous data could erase the modest execution-risk premium quickly. Over 6–18 months, commercial value depends on reproducibility, regulatory acceptance, and the practical size and treatment patterns of the tumor-HI population—not enrollment status alone. Contrarian point: the announcement is operationally positive but not evidence of efficacy. Avoid treating full enrollment as a de-risking event; the binary outcome and potential post-readout funding needs may dominate.

Key Decisions for Investors

• Do not chase RZLT solely on enrollment completion. Treat the December readout as the catalyst, not this update.
• Before taking event risk, verify the study endpoint and analysis plan, expected evaluable sample, cash runway through the readout and follow-up, and current implied volatility. Without those inputs, avoid sizing a directional or options position.
• For existing exposure, keep risk explicitly capped ahead of topline; reassess promptly on any delay, safety signal, or indication that the primary endpoint is not met.
• A favorable headline is not sufficient confirmation: look for clinically meaningful response and durability, acceptable safety, and a credible regulatory path. Failure on those measures would falsify the positive thesis.